[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thyroid-gland-papillary-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thyroid-gland-papillary-carcinoma":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,67,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100633622","personalized-cancer-support-thrive-track-to-manage-the-emotional-needs-of-young-adults-with-thyroid-melanoma-and-testicular-cancer-percs-ya-trial-100633622",false,"NCT07529080","Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial","Personalized Cancer Support for Young Adults","Inclusion Criteria:\n\n* PARTICIPANTS RECRUITED FROM SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS PROGRAM (SEER)-GEORGIA: Age 18-37 at time of cancer diagnosis and age 20-39 at time of enrollment\n* PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Diagnosed with differentiated thyroid cancer (papillary or follicular thyroid cancer), melanoma, or testicular cancer at any stage and reported to the SEER-Georgia registry\n* PARTICIPANTS RECRUITED FROM SEER-GEORGIA: 2-10 years after diagnosis with cancer\n* PARTICIPANTS RECRUITED FROM SEER-GEORGIA: English speaking (able to read and speak English)\n* PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Report of any cancer-related worry (on a 5-point Likert scale from not at all to very worried; those who indicate \"not at all\" will be told the study is focused on those who experience worry)\n* PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Residing in the United States\n* PARTICIPANTS RECRUITED FROM THYROID CANCER SURVIVORS' ASSOCIATION INC. (THYCA): Age 18-37 at time of cancer diagnosis and age 20-39 at time of enrollment\n* PARTICIPANTS RECRUITED FROM THYCA: Diagnosed with differentiated thyroid cancer (papillary or follicular thyroid cancer) at any stage\n* PARTICIPANTS RECRUITED FROM THYCA: 2-10 years after diagnosis with cancer\n* PARTICIPANTS RECRUITED FROM THYCA: English speaking (able to read and speak English)\n* PARTICIPANTS RECRUITED FROM THYCA: Report of any cancer-related worry (on a 5-point Likert scale from not at all to very worried; those who indicate \"not at all\" will be told the study is focused on those who experience worry)\n* PARTICIPANTS RECRUITED FROM THYCA: Residing in the United States\n\nExclusion Criteria:\n\n* PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Subjects from certain vulnerable populations will be excluded as appropriate: fetuses, neonates, children under age 18, prisoners, institutionalized individuals, or others who may be considered vulnerable populations per the National Institutes of Health (NIH) and Office for Human Research Protections (OHRP)\n\n  * It is possible that a subject might be pregnant. Because this involves surveys and reviewing an informational website, participation should have no additional risk for a pregnant woman\n* PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Subjects that do not meet the inclusion criteria\n* PARTICIPANTS RECRUITED FROM THYCA: Subjects from certain vulnerable populations will be excluded as appropriate fetuses, neonates, children under age 18, prisoners, institutionalized individuals, or others who may be considered vulnerable populations per the National Institutes of Health (NIH) and Office for Human Research Protections (OHRP)\n\n  * It is possible that a subject might be pregnant. Because this involves surveys and reviewing an informational website, participation should have no additional risk for a pregnant woman\n* PARTICIPANTS RECRUITED FROM THYCA: Subjects that do not meet the inclusion criteria","ALL","20 Years","39 Years",{"count":20,"type":21},142,"ESTIMATED","INTERVENTIONAL",[24],"NA","This pilot clinical trial is intended to compare the effect of a psychosocial support tool for young adult (YA)cancer survivors - including high-quality information about their cancer combined with evidence-based psychosocial support - to a support tool providing cancer-specific information alone (minus psychosocial modules). This tool, called Thrive Track, will be for YA patients aged 20-39 with thyroid, melanoma, or testicular cancer. Young adult survivors frequently experience persistent worry and distress that can interfere with coping and reduce quality of life. They are also particularly vulnerable to the emotional impact of cancer and may not have adequate support to manage these concerns. The enhanced version of Thrive Track includes personalized emotional support content and strategies designed to help patients better manage worry and distress. Adding these emotional support tools may provide greater benefit than survivorship education alone in strengthening young adult survivors' ability to manage their emotional well-being.",[27,28,29,30,31],"Differentiated Thyroid Gland Carcinoma","Malignant Testicular Neoplasm","Melanoma","Thyroid Gland Follicular Carcinoma","Thyroid Gland Papillary Carcinoma","NOT_YET_RECRUITING","2026-06-23",{"date":35,"type":36},"2026-06-24","ACTUAL",{"date":38,"type":21},"2026-07",{"date":40,"type":21},"2027-08",{"name":42,"class":43},"University of Michigan Rogel Cancer Center","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":44},"100634911","health-and-wellness-coaching-to-improve-adherence-to-healthy-habits-and-treatment-plans-in-papillary-and-follicular-thyroid-cancer-survivors-100634911","NCT07545837","Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors","Health and Wellness Coaching to Improve Patient Activation and Adherence to Healthy Habits in Differentiated Thyroid Cancer Care: A Mixed-Methods Pilot Study","Inclusion Criteria:\n\n* Adults ≥ 18 years\n* Histologically confirmed papillary or follicular thyroid carcinoma\n* Status post total thyroidectomy ± radioactive iodine therapy\n* Receiving levothyroxine monotherapy (no triiodothyronine \\[T3\\] or desiccated thyroid products)\n* Thyroid-stimulating hormone (TSH) \\\u003C 4 uIU\u002FmL at ≥ 3 months post-thyroidectomy\n* English proficiency\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Medullary or anaplastic thyroid carcinoma\n* Current systemic therapy for thyroid or other cancers\n* Cognitive or psychiatric impairment precluding participation\n* Inability to complete study procedures","18 Years",{"count":54,"type":21},20,[24],"This clinical trial evaluates the impact of a patient-centered health and wellness coaching (HWC) intervention on adherence to treatment plans and healthy lifestyle practices in patients with papillary or follicular thyroid cancer. Treatment for thyroid cancer often involves surgery, radioactive iodine and\u002For lifelong levothyroxine with regular monitoring of thyroid stimulating hormone levels. Despite strong survival rates, patients frequently report fatigue, cognitive issues, mood changes, and disruptions in daily life. Treatment burden and psychosocial strain often impair the ability to follow the treatment plan and healthy lifestyle. Studies have shown that HWC motivates patients to take ownership and accountability to perform positive and healthy behavioral changes. HWC may have a positive impact on health-related goal-setting processes and improve self-care and healthcare outcomes in certain settings. It is not yet known how HWC impacts thyroid cancer patients. Incorporating HWC into survivorship care may improve adherence to treatment plans and healthy lifestyle practices in patients with papillary or follicular thyroid cancer.",[30,31],"2026-04-22",{"date":60,"type":36},"2026-04-27",{"date":62,"type":21},"2026-05-26",{"date":64,"type":21},"2027-04-30",{"name":66,"class":43},"Mayo Clinic",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":4,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":44},"100483469","evaluation-of-18f-tfb-petct-scan-in-patients-with-differentiated-thyroid-cancer-100483469","NCT05575440","Evaluation of 18F-TFB PET\u002FCT Scan in Patients With Differentiated Thyroid Cancer","Evaluation of F-18 Tetrafluoroborate (18F-TFB) PET\u002FCT in Patients With Differentiated Thyroid Cancer","Inclusion Criteria:\n\n* Subject has biopsy-proven papillary or follicular thyroid cancer\n* Subject is clinically indicated for 123I-SPECT\u002FCT total body iodine (TBI) scan\n* Subject agrees to undergo 18F-TFB PET\u002FCT scan following TBI scan\n* Karnofsky performance status of \\>= 50 (or Eastern Cooperative Oncology Group \\[ECOG\\]\u002FWorld Health Organization \\[WHO\\] equivalent)\n* Subject is able to be scanned - able to lie still on SPECT\u002FCT and PET\u002FCT scanner table for up to 65 minutes (min)\n* Age 18 or older\n* Ability to understand a written informed consent document, and the willingness to sign it\n* Subject is not pregnant\n\nExclusion Criteria:\n\n* Contrast-enhanced CT within 4 last weeks\n* Amiodarone within last 4 months\n* Ingested iodine, kelp tablets, Lugols iodine, or potassium iodide (SSKI) within 2 weeks\n* Unable to lie flat, still or tolerate a PET scan\n* Applied betadine, iodoform, or quick tanning products to skin within last two weeks\n* If using medication withdrawal for stimulation, then exclude if thyroid stimulating hormone (TSH) level \\\u003C 25\n* Taken anti-thyroid medication within 1 week\n* Subject is breastfeeding\n* Positive pregnancy test",{"count":75,"type":21},24,"OBSERVATIONAL","This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET\u002FCT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET\u002FCT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.",[27,30,31],"RECRUITING","2026-02-24",{"date":82,"type":36},"2026-02-27",{"date":84,"type":36},"2022-04-22",{"date":86,"type":21},"2028-05-01",{"name":66,"class":43},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":44},"100549960","phase-2-vemurafenib-and-cobimetinib-for-the-treatment-of-patients-with-high-risk-differentiated-thyroid-carcinoma-with-brafv600e-mutation-100549960","NCT06440850","Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation","A Pilot Clinical Trial of Vemurafenib and Cobimetinib as a Redifferentiation Strategy in High-Risk, Radioactive Iodine (RAI) Naïve, BRAFV600E Mutated Differentiated Thyroid Carcinoma Patients Undergoing Initial RAI Therapy","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n* Willingness to be followed for about 14 months\n* Males or females aged ≥ 18 years at the time of informed consent\n* Patients with thyroid carcinoma of follicular origin (papillary, follicular or Hurthle cell)\n* Known positive BRAFV600E mutation (determined on a previous analysis and\u002For on a representative formalin-fixed paraffin embedded (FFPE) tumor samples or on a biopsy sample)\n* High risk for recurrence according to the American Thyroid Association (ATA) guideline defined as having one or more of the features below:\n\n  * Gross extrathyroidal extension\n  * FTC with extensive vascular invasion (\\> 4), although less likely to have BRAF mutation\n  * PTC with vascular invasion\n  * Advanced nodal disease of (any node \\>3 cm, \\> 4 nodes, or extra-nodal extension)\n  * BRAF+TERT promoter mutation\n  * Post op thyroglobulin (TG) suggestive of distant metastasis\n  * Distant metastatic sites (only for exploratory arm)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n* Blood pressure (BP) ≤ 140\u002F90 mm Hg at screening with or without antihypertensive medications and no change in antihypertensive medications within 1 week prior to treatment start\n* Creatinine clearance ≥ 50 mL\u002Fmin according to the Cockcroft and Gault formula\n* Absolute neutrophil count (ANC) ≥ 1.5 x 109\u002FL\n* Hemoglobin ≥ 9.0 g\u002FdL\n* Platelet count ≥ 100 x 109\u002FL\n* Normal blood coagulation function as evidenced by an International Normalized Ratio (INR) ≤ 1.5\n* Bilirubin ≤ 1.5 × upper limit of normal (ULN) except for unconjugated hyperbilirubinemia or Gilbert's syndrome\n* Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 3 × ULN (≤ 5 × ULN if subject has liver metastases)\n* Women of childbearing potential must have a negative urine or serum β-HCG pregnancy test within 7 days prior to the administration of the first study treatment\n* Agreement by women of childbearing potential (WOCBP) and males of childbearing potential\\* to use an effective\\*\\* method of birth control\\*\\* for at least 3 months prior to screening through 1 year of study follow-up.\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only)\n\n    * Effective birth control defined as hormonal and\u002For barrier contraception\n* Non-English speaking persons and adults lacking capacity to consent are not excluded from participation\n\nExclusion Criteria:\n\n* Prior RAI treatment\n* Prior anti-BRAF, anti-MEK treatment such as sorafenib, dabrafenib, vemurafenib, encorafenib, binimetinib, cobimetinib, trametinib, d selumitinib and other TKIs like, lenvatinib, sunitinib, axitinib, cabozantenib, vandatinib, pazopanib use\n* Low to intermediate risk differentiated thyroid cancer (DTC) cases (not having the high-risk features as described above)\n* RAI contraindication\n* Undifferentiated or Medullary (MTC) carcinoma of the thyroid\n* Major surgery within 4 weeks prior to the first dose of treatment\n* Subjects having \\> 1 + proteinuria on urine dipstick testing will undergo 24 h urine collection for quantitative assessment of proteinuria. Subjects with urine protein ≥ 1 g\u002F24 h will be ineligible\n* Need for locoregional treatment such as surgery, external beam radiation or thermoablation at inclusion\n* External beam radiation, for thyroid cancer, \\\u003C4 weeks prior initiation of treatment\n* Gastrointestinal malabsorption or any other condition that in the opinion of the investigator might affect the absorption of the drugs\n* History of congestive heart failure greater or equal to than New York Heart association (NYHA) Class II, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of treatment, or cardiac arrhythmia associated with significant cardiovascular impairment and uncontrolled hypertension\n* Electrocardiogram (ECG) with QT interval (QTc) interval ≥ 480 msec\n* Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 2 months prior to the first dose of treatment and any other active bleeding, coagulopathy or pathologic condition that would confer a high risk of bleeding\n* Active infection requiring systemic therapy\n* Active malignancy (except for DTC, or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or bladder) within the past 24 months\n* Any history of or concomitant medical condition that, in the opinion of the investigator, would compromise subject's ability to safely complete the protocol\n* Females who are pregnant or breastfeeding\n* Patients with an injection of radio-contrast agent within 12 weeks prior to enrollment (can be enrolled after 12 weeks)\n* Previous history of retinal vein occlusion\n* Previous history of central serious retinopathy\n* Known hypersensitivity to the study drugs or to any of the excipients\n* Any other condition (including psychosocial condition) that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Any other condition that would confound study results\n* Noncompliance\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)",{"count":96,"type":21},21,[98],"PHASE2","This phase II trial tests how well vemurafenib and cobimetinib work in treating patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy. Vemurafenib and cobimetinib are used in patients whose cancer has a mutated (changed) form of a gene called BRAF. They are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving vemurafenib and cobimetinib may work better to treat patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy.",[30,101,31],"Thyroid Gland Oncocytic Carcinoma","2026-01-29",{"date":104,"type":36},"2026-02-02",{"date":106,"type":36},"2024-07-15",{"date":108,"type":21},"2026-11-22",{"name":110,"class":43},"City of Hope Medical Center"]